表紙
市場調査レポート

腋窩多汗症:パイプライン製品の分析

Axillary Hyperhidrosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 288826
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
腋窩多汗症:パイプライン製品の分析 Axillary Hyperhidrosis - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 55 Pages
概要

腋窩多汗症とは、腋の下から過剰な量の汗がで続けれることを指します。主な症状として、湿り気(に伴う不快感ほか)などがあります。主な治療法として、抗コリン作動薬や外科手術、発汗抑制剤などがあります。

当レポートでは、世界各国での腋窩多汗症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

腋窩多汗症の概要

治療薬の開発

  • 腋窩多汗症向けパイプライン製品:概要
  • 腋窩多汗症向けパイプライン製品:比較分析

各企業で開発中の腋窩多汗症治療薬

パイプライン製品の概略

  • 治験段階の製品

腋窩多汗症治療薬:開発中の製品の一覧(企業別)

腋窩多汗症治療薬の開発に従事している企業

  • Actavis plc
  • Brickell Biotech, Inc.
  • Dermira Inc.
  • GlaxoSmithKline plc
  • Revance Therapeutics, Inc.
  • TheraVida, Inc.

腋窩多汗症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ANT-1403
  • BBI-4000
  • DRM-04
  • onabotulinumtoxin A
  • oxybutynin chloride
  • RT-001
  • solifenacin
  • umeclidinium bromide

腋窩多汗症治療薬:パイプライン製品の最新動向

腋窩多汗症治療薬:開発が休止状態の製品

腋窩多汗症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7913IDB

Summary

Global Markets Direct's, 'Axillary Hyperhidrosis - Pipeline Review, H1 2016', provides an overview of the Axillary Hyperhidrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis
  • The report reviews pipeline therapeutics for Axillary Hyperhidrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Axillary Hyperhidrosis therapeutics and enlists all their major and minor projects
  • The report assesses Axillary Hyperhidrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Axillary Hyperhidrosis Overview
  • Therapeutics Development
    • Pipeline Products for Axillary Hyperhidrosis - Overview
  • Axillary Hyperhidrosis - Therapeutics under Development by Companies
  • Axillary Hyperhidrosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Axillary Hyperhidrosis - Products under Development by Companies
  • Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Brickell Biotech, Inc.
    • Dermira Inc.
    • GlaxoSmithKline Plc
    • Revance Therapeutics, Inc.
    • TheraVida, Inc.
  • Axillary Hyperhidrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANT-1207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANT-1403 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • daxibotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DRM-04 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxybutynin chloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sofpironium bromide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • umeclidinium bromide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Axillary Hyperhidrosis - Recent Pipeline Updates
  • Axillary Hyperhidrosis - Product Development Milestones
    • Featured News & Press Releases
      • Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
      • Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
      • Jan 07, 2016: Dermira Provides DRM04 Development Program Update
      • Dec 23, 2015: Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
      • Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
      • Sep 28, 2015: Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines
      • Sep 09, 2015: Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
      • Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
      • Jun 03, 2015: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
      • Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Axillary Hyperhidrosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Axillary Hyperhidrosis - Pipeline by Allergan Plc, H1 2016
  • Axillary Hyperhidrosis - Pipeline by Brickell Biotech, Inc., H1 2016
  • Axillary Hyperhidrosis - Pipeline by Dermira Inc., H1 2016
  • Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Axillary Hyperhidrosis - Pipeline by Revance Therapeutics, Inc., H1 2016
  • Axillary Hyperhidrosis - Pipeline by TheraVida, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Axillary Hyperhidrosis Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

  • Number of Products under Development for Axillary Hyperhidrosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top